time points in the assessment of mrd
Published 5 years ago • 108 plays • Length 6:31Download video MP4
Download video MP3
Similar videos
-
6:20
mrd testing in all: sensitivity and availability
-
4:30
mrd testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trials
-
6:08
mrd assessment and its clinical implications in aml
-
6:23
role of mrd assessment in multiple myeloma
-
5:51
establishing mrd’s role in all management
-
7:19
prognostic significance of mrd in aml
-
5:44
the future of mrd assessment in crc
-
4:08
future directions for mrd testing in all
-
57:50
immunopet- an advanced companion to mrd testing
-
8:53
how is mrd testing done?
-
7:42
what is mrd?
-
4:43
mrd assessment and consolidation in aml
-
14:39
assessing the utility of mrd measures versus ct scans
-
8:53
all: when and who to test for minimal residual disease
-
1:47
depth of mrd assessment in mm
-
5:40
sensitivity of mrd testing and impact on decisionmaking in all
-
0:57
dr. daver discusses use of mrd assessment in hematologic malignancies
-
6:36
impact of mrd assessment on myeloma treatment
-
3:22
translating mrd assessment into routine clinical practice
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?
-
1:26
mrd in myeloma: the fda perspective
-
2:18
the utility of measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)